• Phebestin as an Aminopeptidase Inhibitor for Malaria Therapy

  2026-04-22

  This article analyzes the recent evaluation of phebestin, a bestatin-related aminopeptidase inhibitor, demonstrating its nanomolar efficacy against Plasmodium falciparum and potent activity in resistant malaria models. The study’s findings have significant implications for targeting parasite proteolytic pathways and underscore the need for novel antimalarial agents given rising drug resistance.

• P2RX1 Drives Mitochondrial Apoptosis via CaMKII in Ph+ ALL

  2026-04-22

  Li et al. reveal that P2RX1 overexpression promotes mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) by modulating calcium/CaMKII and suppressing PI3K/Akt signaling. These insights suggest P2RX1 as a potential therapeutic target and provide mechanistic clarity for apoptosis pathway interrogation in Ph+ ALL.

• Cy5-UTP: Advancing RNA Labeling for Translational Impact

  2026-04-21

  This thought-leadership article explores how Cy5-UTP (Cyanine 5-uridine triphosphate) is redefining fluorescent RNA labeling for translational research. Blending mechanistic insight, protocol guidance, and competitive benchmarking, it offers strategic recommendations for researchers navigating complex RNA-centric workflows—from mRNA nanovaccine tracking to multiplexed FISH. The discussion bridges foundational findings with clinical ambitions, referencing recent advances in dual immunoregulatory mRNA nanovaccine research for autoimmune disease. We position Cy5-UTP as a linchpin for innovation, highlighting its unique mechanistic value and practical utility as supplied by APExBIO.

• O-GlcNAcylation Drives Wnt-Induced Glycolysis in Bone Format

  2026-04-21

  This study uncovers how O-GlcNAcylation, regulated via Ca2+-PKA-GFAT1 and Wnt–β-catenin pathways, is essential for Wnt-stimulated bone formation by rewiring aerobic glycolysis. The findings provide mechanistic insight into metabolic control of osteogenesis and highlight O-GlcNAcylation as a potential target for bone-anabolic therapies.

• S Tag Peptide (A6007): Practical Guidance for Fusion Tag Wor

  2026-04-20

  S Tag Peptide addresses persistent challenges in recombinant protein detection, purification, and solubility enhancement—especially for proteins prone to aggregation or poor expression. It is most effective when genetically fused to target proteins for downstream affinity-based workflows, but should not be used in applications requiring standalone enzymatic activity or in ethanol-based systems.

• MDV3100 (Enzalutamide): Mechanistic Insights into AR Pathway

  2026-04-20

  Explore how MDV3100 (Enzalutamide) advances prostate cancer research by dissecting androgen receptor signaling and unveiling new resistance mechanisms through glycosaminoglycan biosynthesis. This article delivers in-depth mechanistic analysis, practical assay guidance, and unique integration of the latest reference findings.

• Angiotensin III: Applied Workflows for RAAS and Receptor Stu

  2026-04-19

  Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe) is a powerful tool for dissecting the renin-angiotensin-aldosterone system in cardiovascular and neuroendocrine models. This article delivers actionable protocol enhancements, troubleshooting insights, and critical cross-domain analysis, leveraging the latest mechanistic findings and APExBIO’s validated peptide.

• Angiotensin III: Advanced Workflows for RAAS and Viral Resea

  2026-04-18

  Angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe) uniquely enables rigorous RAAS investigations and emerging viral pathogenesis models. Learn how APExBIO’s high-purity peptide streamlines experimental design, troubleshooting, and cross-domain research with robust, reproducible results.

• 5-Azacytidine for DNA Demethylation: Applied Workflows & Ins

  2026-04-17

  5-Azacytidine (5-AzaC) is transforming epigenetic research through its potent DNA demethylation capabilities, enabling reactivation of silenced genes and induction of cancer cell dormancy. Discover protocol enhancements, practical troubleshooting, and advanced applications—directly informed by recent metastasis research and APExBIO’s rigorously validated compound.

• Tacalcitol Monohydrate Induces NGF in Human Keratinocytes

  2026-04-16

  This study demonstrates that Tacalcitol monohydrate, a synthetic analog of vitamin D3, transcriptionally upregulates nerve growth factor (NGF) production in human epidermal keratinocytes. The findings provide mechanistic insight into NGF regulation in skin, informing both dermatological and neuroprotective research applications.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetic M

  2026-04-15

  This study presents a streamlined protocol to generate human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, offering improved reproducibility and physiological relevance for pharmacokinetic studies. The findings address current limitations in in vitro drug absorption and metabolism assays, enabling more accurate evaluation of orally administered compounds.

• EZH2 Inhibition and 5-Azacytidine Restore Immunity in PTEN-D

  2026-04-14

  This study demonstrates that dual epigenetic targeting with EZH2 inhibition and 5-azacytidine synergistically overcomes immune evasion in PTEN-deficient glioblastoma by restoring the ERV-MAVS-IFN viral mimicry pathway. The findings highlight a rational combination strategy to remodel the tumor microenvironment and enhance antitumor immunity in resistant gliomas.

• Mapping GCGR Small Molecule Binding: Insights from MK 0893 C

  2026-04-13

  Wang et al. (2024) integrate GCGR crystal structures and molecular dynamics to identify and validate inferential binding sites for small-molecule antagonists, using MK 0893 as the structural benchmark. Their findings clarify the site diversity and binding stability of clinical GCGR antagonists, guiding future type 2 diabetes drug discovery.

• 5-Azacytidine in Precision DNA Demethylation: Translational

  2026-04-13

  Explore the multifaceted role of 5-Azacytidine as a DNA demethylation agent with a focus on translational research value and protocol guidance. This article delivers a unique perspective by bridging clinical epigenetics breakthroughs with advanced laboratory assay optimization.

• BMX Kinase Modulates Lysosomal Acidification in Tuberculosis

  2026-04-12

  A recent Nature Communications study uncovers how Mycobacterium tuberculosis (Mtb) manipulates host cell lysosomal acidification to enhance its intracellular survival by exploiting BMX kinase-mediated phosphorylation of ATP6V1E1. This mechanistic insight opens new avenues for host-directed therapies and provides a foundation for evaluating BMX kinase inhibitors in infection models.

10140 records 1/676 page Next 12345 下5页 Last page